Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 9/20 | 0.61 |
| ▸ | LGALS9 | O00182 | 7/20 | 0.61 |
| ▸ | LGALS1 | P09382 | 7/20 | 0.61 |
| ▸ | LGALS7; LGALS7B | P47929 | 6/20 | 0.61 |
| ▸ | LGALS8 | O00214 | 6/20 | 0.48 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | SELP | P16109 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SELE | P16581 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13804416 | 1.00 | LGALS3 (0.61) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL14900285 | 1.00 | LGALS3 (0.61) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL13804400 | 1.00 | LGALS3 (0.61) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL14878331 | 1.00 | LGALS3 (0.61) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL14546394 | 0.92 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL15086135 | 0.92 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL14878341 | 0.92 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL15086161 | 0.92 | LGALS3 (0.50) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL16330468 | 0.90 | LGALS9 (0.48) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 | |
| SCHEMBL14900286 | 0.90 | LGALS9 (0.48) | LGALS3LGALS9LGALS1LGALS7; LGALS7BLGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222381-B2 | Derivatives of monosaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2012-07-17 | — | — | US | disclosed |
| US-20090163373-A1 | Method of Drug Design | ALCHEMIA LIMITED (AU) | 2009-06-25 | — | — | US | disclosed |
| US-20080009418-A1 | Selective Inhibitors | ALCHEMIA LTD. (AU) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009418-A1 | Selective Inhibitors | MCL1, ABCG2, GDI2 | LGALS3 2903/4885LGALS9 2777/4885LGALS1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.